




PHARMACEUTICAL 2019

Collectar Biosciences Inc.
Rank 163 of 363





PHARMACEUTICAL 2019

Collectar Biosciences Inc.
Rank 163 of 363

The relative strengths and weaknesses of Collectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Collectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 114%, being 77% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	13,952
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,622
Liabilities, Non-Current	171
Other Assets	559
Other Compr. Net Income	0
Other Expenses	1,675
Other Liabilities	0
Other Net Income	92
Other Revenues	0
Property and Equipment	543
Research and Development	6,835
Selling, General and Administrative Expense	4,820

Output Variable	Value in 1000 USD
Assets	15,054
Liabilities	1,793
Expenses	13,331
Revenues	0
Stockholders Equity	13,261
Net Income	-13,239
Comprehensive Net Income	-13,239
Economic Capital Ratio	114%